nChroma Bio Halves Staff, Halts Hepatitis Trial
The Boston biotech is cutting roughly half its employees after pausing enrollment in its lead hepatitis B study, CRMA-1001.
Updated on Nov. 19, 2026 in Biotech

Boston-based nChroma Bio is restructuring after halting enrollment in its phase 1/2 trial of CRMA-1001, a liver-directed epigenetic silencer evaluated as a potential functional cure for chronic hepatitis B. The company says roughly half of its employees will leave as it evaluates strategic alternatives for its programs.
Why it matters
The move marks a second round of layoffs at nChroma Bio within 12 months and leaves its lead hepatitis asset without an active trial. For the Boston biotech sector, it signals how quickly early-stage programs can be scaled back when companies reassess their pipelines.
The figures available are a company statement that roughly half of nChroma Bio's employees will leave and a $75 million combined funding total for the merged companies. The company has not disclosed exact headcounts, and the future of its programs remains under strategic review.
The players
nChroma Bio
A Boston-based biotechnology company developing epigenetic therapies, formed through a merger of two companies with $75 million in combined funding.
The details
nChroma Bio announced the halt of enrollment in its phase 1/2 study of CRMA-1001 in a LinkedIn post, and a spokesperson told Fierce the company is restructuring. The study had begun in January, and the decision followed an undisclosed layoff in November 2025.
Timeline
November 2025: nChroma Bio laid off an undisclosed number of employees.
January 2026: The phase 1/2 study of CRMA-1001 began.
November 18, 2026: The company announced the halt of enrollment on LinkedIn.
Industry Trajectory
Early-stage Boston biotechs have increasingly cut staff and paused trials after initial funding rounds, and nChroma Bio's second layoff in 12 months follows that pattern. The halt of CRMA-1001 shows how a single lead asset can determine whether a company survives a strategic review.
Patients with chronic hepatitis B who were hoping for a functional cure from CRMA-1001 will not see that trial continue for now. Employees and contractors in Boston's biotech sector face direct job losses as roughly half of nChroma Bio's staff depart.
The takeaway
Early-stage biotech funding can shift quickly, and a single trial halt can reshape an entire company. Readers tracking hepatitis B research should watch for any updates on CRMA-1001's future or a strategic partner.
Further reading
For more on the sector, see Biotech coverage across the region.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.






